These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30442825)

  • 61. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L
    Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
    Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
    Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In older adults, new use of allopurinol or febuxostat was linked to hypersensitivity reactions versus colchicine.
    Schattner A
    Ann Intern Med; 2020 Jul; 173(2):JC10. PubMed ID: 32687746
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
    Becker MA; MacDonald PA; Hunt B; Gunawardhana L
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
    Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
    Koide H; Hira D; Tsujimoto M; Katsube Y; Minegaki T; Uzu T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
    Biol Pharm Bull; 2017; 40(5):681-686. PubMed ID: 28458354
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients.
    Guedes M; Zhao J; LaMoreaux B; Marder B; Gorlitsky B; Domingues V; Rivara MB; Lew S; Robinson B; Pecoits-Filho R; Karaboyas A;
    Kidney360; 2023 Jan; 4(1):54-62. PubMed ID: 36700904
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis".
    Gao L; Wang B; Cheng R
    Clin Cardiol; 2022 Jul; 45(7):687-690. PubMed ID: 35634754
    [No Abstract]   [Full Text] [Related]  

  • 75. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
    Chohan S
    J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
    Deng JH; Zhang JX
    Clin Cardiol; 2022 Jul; 45(7):685-686. PubMed ID: 35634752
    [No Abstract]   [Full Text] [Related]  

  • 77. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of gout in the older adult.
    Fravel MA; Ernst ME
    Am J Geriatr Pharmacother; 2011 Oct; 9(5):271-85. PubMed ID: 21849262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.